twincretin therapy

Twincretin Therapy – SURPASSing Expectations

R92.00 incl VAT

Evidence of the presence of gut-secreted ‘incretin’ hormones that help to promote secretion of insulin by the pancreatic beta cells was discovered almost a century ago. It then took many decades before the two best-studied incretins, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were isolated in 1971 and 1983, respectively. Although GIP was the first incretin to be isolated, its function remained unclear, and the multiple physiological effects of GLP-1 made it an obvious drug target for treatment of type 2 diabetes mellitus. Exenatide was the first GLP-1 receptor agonist to be approved by the United States Food and Drug Administration (FDA) in 2005, followed in later years by several analogues of human GLP-1 with enhanced benefits.

Only in recent years has research investigated the synergistic action of GLP-1 and GIP and the translation of this synergy into a pharmacotherapy. GIP and GLP-1 receptors are both found in pancreatic cells, where the co-activation results in a larger glucagonostatic effect, greater reductions in food intake, body weight and fat mass and enhancement of insulin secretion and sensitivity than the administration of GLP-1 alone.

welcome to
CDE ACADEMY

CDE ACADEMY

Login to your account

Welcome to the CDE Academy

Subscribe to our

Newsletters

(Please note that subscribing here does NOT register you for any CDE Course)